[Targeting the RAS signalling pathway in cancer]

Area of Science:

• Oncology
• Molecular Biology
• Cancer Signaling

Background:

• RAS proteins are key regulators of the cell cycle.
• The RAS signaling pathway influences cell survival and angiogenesis via downstream pathways like RAF/MEK/ERK and PI3K/AKT/mTOR.
• Alterations in the RAS pathway are implicated in various cancers, leading to the development of targeted therapies.

Purpose of the Study:

• To review the regulation of RAS proteins in cancer.
• To detail the main RAS downstream signaling pathways.
• To discuss therapeutic strategies targeting RAS and its effectors, including predictive value of RAS mutations for EGFR-targeted agents.

Main Methods:

• Literature review of RAS protein regulation in cancer.
• Analysis of RAS downstream signaling pathways.
• Discussion of targeted therapeutic approaches and predictive biomarkers.

Main Results:

• The RAS pathway's role in cell cycle, survival, and angiogenesis is multifaceted.
• Numerous targeted agents acting on the RAS pathway components are in clinical use.
• RAS mutations can predict patient response to specific therapies, particularly EGFR inhibitors.

Conclusions:

• Targeting the RAS pathway offers significant therapeutic potential in oncology.
• Understanding RAS signaling is critical for developing effective cancer treatments.
• RAS mutation status is an important biomarker for guiding treatment decisions in certain cancers.